The Only Documented Tenfold at Altos Labs Is a Salary

The Elle Germany piece opens with roughly two hundred words about Altos Labs: the Silicon Valley longevity company that launched in January 2022 with three billion dollars in funding from Jeff Bezos and Yuri Milner, its scientific board stocked with Nobel laureates including Shinya Yamanaka, Jennifer Doudna, Frances Arnold and David Baltimore. Then, with no more transition than a link reading "order directly here," the piece pivots to its real subject: a Dermalogica SPF50 day cream, sold on its oleosome-carried UV filters and peptide blend, under a headline promising skin that ages optically ten times slower.

Altos Labs states its mission plainly on its own site: to restore cell health and resilience through cell rejuvenation, to reverse disease, injury and the disabilities that occur throughout life. That is cellular reprogramming research built on Yamanaka factors, aimed eventually at disease and tissue repair, not at a store shelf. Nothing on the site, and nothing in the company's public research to date, mentions skincare, sunscreen or any topical product. Altos Labs has not endorsed this cream, tested it or funded research connected to it. It appears in the piece for the credibility its name carries, not for anything it did.

The number that never gets sourced

Read the roughly seven hundred words that follow the headline, and the figure ten times appears exactly once: in the title. The body names real ingredients: avobenzone and octinoxate as UV filters, safflower oleosomes carrying them, palmitoyl tripeptide-5 and glucosamine for collagen support, glycerin and sodium hyaluronate for hydration. None of that is invented; it matches the product's registered formulation. What never appears is a study, a trial or a methodology attached to the tenfold multiplier in the headline. It is not explained, footnoted or repeated anywhere in the piece. It functions as a number, not a finding.

There is a documented tenfold connected to Altos Labs. It just is not this one. Recruiting scientists in 2021, the company offered packages that biologist Manuel Serrano described to MIT Technology Review as five to ten times what he earned at the time.

Sports-star salaries of a million dollars a year or more, plus equity, for the researchers Altos wanted most.

That multiplier is about payroll, not photoaging.

Genuine evidence on sunscreen and visible aging exists, and it is more modest than either number attached to this story. A randomized trial run in Nambour, Australia, published in Annals of Internal Medicine in 2013, found that adults assigned to daily sunscreen use showed twenty four percent less photoaging, measured by skin surface microtopography, than adults using sunscreen at their own discretion, over four and a half years. That is a real, replicable effect of sun protection. It has nothing to do with a peptide blend, an oleosome or a Nobel laureate's name, and it took four and a half years of measurement to demonstrate, not a headline.

Sources: Altos Labs · Dermalogica · Annals of Internal Medicine